As COVID-19, caused by SARS-CoV-2, spreads worldwide, various patterns of associated dermatologic diseases continue to emerge. Early reports classified multiple cutaneous manifestations of SARS-CoV-2 infection.1 In this article, we report the observation of a newly associated mucocutaneous eruption in a pediatric patient with confirmed SARS-CoV-2 infection.
A previously healthy 17-year-old male presented to the emergency department with 3 days of mouth pain and nonpainful penile erosions. One week prior, he experienced transient anosmia and ageusia that had since spontaneously resolved. At that time, he was tested for SARS-CoV-2 infection via nasopharyngeal polymerase chain reaction (PCR), the results of which were positive. He denied fever, cough, dyspnea, rhinorrhea, and gastrointestinal symptoms at any time. Although he had taken acetaminophen and ibuprofen before presenting to the emergency department, he took no medications before the onset of his mucocutaneous eruption.